Consistent with our mission, we are asking Congress, the Administration, and state legislatures to support medical research to find cures for IBD, and to improve patient access to care. Below are our legislative priorities. Where appropriate, we indicate federal bills and provide links where you can learn more about state-based legislation. Speak out to help improve research funding and patient care nationwide. Together, we can make a difference.
Access to Care
Medical Research
Minorities are underrepresented in most clinical trials - this creates a line of disconnect and skewed information regarding ethnic/racial responses to medication and treatments.
Participants in clinical trials should represent the patients that will use the medical products. This is often not the case--racial and ethnic minorities are underrepresented in clinical research. This is a concern because people of different ages, races, and ethnicities, may react differently to medical products. We are committed to working with companies to change this.
REGISTRATION OPEN!
We are hosting our #EquityInIBD Hybrid Patient Symposium focused on the Black Indigenous People of Color (BIPOC) Patient community, on Sept 18th. This is the first patient symposium of its kind.
We are excited to extend opportunities that will increase education, awareness and disease management to our community.
If your answer is YES to any of these questions:
-
Are you interested in decreasing disparities?
-
Are you interested in engaging with REAL patients?
-
Are you interested in learning more about IBD and the presentations in black and diverse patient populations?
-
Are you a patient who is looking for more answers and resources?
-
Are you a care partner who is in need of support with navigating healthcare within IBD?
-
Are you concerned about clinical trials and research?
-
Are you a clinician working in equity?
-
Are you looking to network with other patient leaders, advocacy organizations, and industry leaders?
You should be here!
Attend the Main Session or Join us at Table Talks:
-
Celiac Disease
-
Irritable Bowel Syndrome
-
Medical Nutrition Therapy (MNT)
-
Mental Health & Digestive Disease
-
Pediatric Gastroenterology
-
Understanding Disability (SSDI)
Details

Location:
Hilton Washington DC National Mall The Wharf
480 L'Enfant Plaza SW
Washington, DC
20024
Date: September 18th, 2021
Hybrid Event (Virtual & Onsite)
Our maximum onsite capacity with social distancing is 75 attendees
All Attendees are required to send proof of vaccination
**You will be able to schedule time at a table in July.
REGISTRATION
OPENS
MAY 19TH,
2021


September 18th


Announcements
.png)
We are excited to announce

Sponsors
Johnson & Johnson aspires to help eradicate racial and social injustice as a public health threat by eliminating health inequities for people of color.
People First Culture
Cultivate one of the most diverse and inclusive workforces that inspires innovative healthcare solutions around the world.
Healthier Communities
Help close the racial mortality gap by investing in culturally competent community care models that create health outcomes for people of color.
Enduring Alliances
Lead and leverage J&J's powerful partnership network to combat racial and social health determinants.
Equity Architect

"Amgen is committed to understanding and working to help reduce long standing healthcare inequities, including in clinical trials, where communities of color are disproportionately represented. As Amgen’s CEO and Chairman, Bob Bradway, has stated, “Healthcare equity has been an elusive dream in our society, but it doesn’t have to be an elusive dream,” “We’re committed to working on it in the short-term and in the long-term, and we accept that this is likely to be a journey of a thousand miles but it’s one that we want to be part of"
Equity Collaborator

Equity Collaborator

"Amgen is committed to understanding and working to help reduce long standing healthcare inequities, including in clinical trials, where communities of color are disproportionately represented. As Amgen’s CEO and Chairman, Bob Bradway, has stated, “Healthcare equity has been an elusive dream in our society, but it doesn’t have to be an elusive dream,” “We’re committed to working on it in the short-term and in the long-term, and we accept that this is likely to be a journey of a thousand miles but it’s one that we want to be part of"

"PhRMA and the biopharmaceutical industry are committed to driving real change and improving health outcomes for patients in underserved communities. Equity is critical to the health and well-being of Black and Brown communities and it remains essential to a robust ecosystem of innovation. America’s biopharmaceutical companies are pushing for necessary systemic long-term change to better meet the needs of Black and Brown America including advancing policy solutions and research to better address health disparities and earning trust and addressing systemic issues that deter certain communities from participating in clinical trials, so that those who want to participate can."